XML 100 R43.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income tax expense | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Taxes [Abstract] |
Income tax expense | D.30. Income tax expense Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States. The table below shows the allocation of income tax expense between current and deferred taxes:
(€ million) | 2024 | 2023 | (a) | 2022 | (a)
Current taxes | (2,152) | (2,251) |  | (2,631) |
Deferred taxes | 948 | 1,234 |  | 722 |
Total | (1,204) | (1,017) |  | (1,909) |
Income before tax and investments accounted for using the equity method | 6,698 | 6,251 |  | 9,937 |
(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows:
(%) | 2024 | 2023 | (a) | 2022 | (a)
Standard tax rate applicable in France | 25.8 | 25.8 |  | 25.8 |
Difference between the standard French tax rate and the rates applicable to Sanofi(b) | (13.3) | (15.3) |  | (6.9) |
Revisions to tax exposures and settlements of tax disputes | 2.8 | 3.1 |  | (0.8) |
Fair value remeasurement of contingent consideration |  | 0.1 |  | (0.2) |
Other items(c) | 2.7 | 2.6 |  | 1.3 |
Effective tax rate | 18.0 | 16.3 |  | 19.2 |
(a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b)The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For the year ended December 31, 2024, this line includes a tax expense of €58 million, representing the estimated impact of Pillar Two based on Sanofi’s current understanding of Pillar Two rules. (c)In determining the amount of the deferred tax liability for 2024, 2023 and 2022, Sanofi took into account changes in the ownership structure of certain subsidiaries. For the periods presented, the amount of deferred tax assets recognized in profit or loss that were initially subject to impairment losses at the time of a business combination is immaterial.

X
- Definition The entire disclosure for income taxes. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 12 -IssueDate 2023-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfIncomeTaxExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Income Taxes [Abstract] + References No definition available. + Details
Name: | sny_IncomeTaxesAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration